Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Oliver Sartor MD

Oliver Sartor MD

Director of the Radiopharmaceutical Trials, Chief of the Genitourinary Cancer Malignancy Group, Mayo Clinic, Rochester, Minnesota

Dr. Oliver Sartor is a medical oncologist in the Division of Medical Oncology in the Department of Oncology at the Mayo Clinic in Rochester, Minnesota. He serves as Chair of the Genitourinary Cancer Disease Group and the Director of Radiopharmaceutical Clinical Trials for the Mayo Clinic Comprehensive Cancer Center.

Dr. Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 500 peer-reviewed articles, led or co-led multiple national and international clinical studies, including four phase III studies pivotal for FDA approval of drugs for advanced prostate cancer (Quadramet, Xofigo, Pluvicto, and Jevtana). He has lectured widely, and, at last count, has given invited lectures in 33 countries. He is the Medical Oncology Chair of the Genitourinary Cancer Committee of NRG, a national cancer research group.

Disclosures

  • Consultant: Advanced Accelerator Applications (AAA); Astellas; AstraZeneca; Bayer; Blue Earth Diagnostics; Bavarian Nordic; Bristol Myers Squibb; Clarity Pharmaceuticals; Clovis; Constellation; Dendreon; EMD Serono; Fusion; Isotopen Technologien Muenchen; Janssen; Merck; Myovant; Myriad; Noria Therapeutics; Novartis; Noxopharm; Progenics; POINT Biopharma; Pfizer; Sanofi; Teneobio; Telix; Theragnostics
  • Research funding: Advanced Accelerator Applications; Amgen; AstraZeneca; Bayer; Constellation; Endocyte; Invitae; Janssen; Lantheus; Merck; Progenics; Teneobio

Recent Contributions to PracticeUpdate:

  1. Diagnostic Performance of 18F-DCFPyL PET/CT in Men With Biochemically Recurrent Prostate Cancer
  2. Diagnostic Accuracy of Prostate Specific Membrane Antigen 18F-DCFPyL PET/CT in Prostate Cancer Patients
  3. Cabazitaxel vs Abiraterone or Enzalutamide in Poor Prognosis Metastatic Castration-Resistant Prostate Cancer
  4. Lutetium-177 PSMA-617 Improves Survival of mCRPC
  5. Adjuvant Radiation Therapy After Radical Prostatectomy Decreases All-Cause Mortality
  6. Is the Triplet Regimen Standard of Care for Metastatic Castrate-Sensitive Prostate Cancer?
  7. FDA Approves Second PSMA-Targeted PET Imaging Drug for Men With Prostate Cancer
  8. Treatment of Metachronous Metastatic Hormone-Sensitive Prostate Cancer With Enzalutamide and ADT
  9. Molecular Subtypes Associated With Different Responses to Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer
  10. Adding Bone Protective Agents to Enzalutamide and Radium-223 for mCRPC

Most Read This Week

Recently Updated